

Mercedes

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3451329/publications.pdf>

Version: 2024-02-01

26
papers

1,053
citations

430874

18
h-index

552781

26
g-index

26
all docs

26
docs citations

26
times ranked

1908
citing authors

#	ARTICLE	IF	CITATIONS
1	Epithelial-to-Mesenchymal Transition Mediates Docetaxel Resistance and High Risk of Relapse in Prostate Cancer. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 1270-1284.	4.1	131
2	Identification of Docetaxel Resistance Genes in Castration-Resistant Prostate Cancer. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 329-339.	4.1	92
3	Utility of Fluorescence In Situ Hybridization as a Non-invasive Technique in the Diagnosis of Upper Urinary Tract Urothelial Carcinoma. <i>European Urology</i> , 2007, 51, 409-415.	1.9	73
4	Gene Expression Signature in Urine for Diagnosing and Assessing Aggressiveness of Bladder Urothelial Carcinoma. <i>Clinical Cancer Research</i> , 2010, 16, 2624-2633.	7.0	70
5	Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , 2019, 75, 368-373.	1.9	64
6	TMPRSS2-ERG in Blood and Docetaxel Resistance in Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , 2016, 70, 709-713.	1.9	63
7	SPARC mediates metastatic cooperation between CSC and non-CSC prostate cancer cell subpopulations. <i>Molecular Cancer</i> , 2014, 13, 237.	19.2	60
8	Nuclear IGF-1R predicts chemotherapy and targeted therapy resistance in metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2017, 117, 1777-1786.	6.4	58
9	Clinical Utility of Fluorescent in situ Hybridization for the Surveillance of Bladder Cancer Patients Treated with Bacillus Calmette-Guérin Therapy. <i>European Urology</i> , 2007, 52, 752-759.	1.9	53
10	Nuclear factor- κ B and interleukin-6 related docetaxel resistance in castration-resistant prostate cancer. <i>Prostate</i> , 2013, 73, 512-521.	2.3	52
11	Molecular Lymph Node Staging in Bladder Urothelial Carcinoma: Impact on Survival. <i>European Urology</i> , 2008, 54, 1363-1372.	1.9	40
12	The Transmodulation of HER2 and EGFR by Substance P in Breast Cancer Cells Requires c-Src and Metalloproteinase Activation. <i>PLoS ONE</i> , 2015, 10, e0129661.	2.5	34
13	Utility of a multiprobe fluorescence in situ hybridization assay in the detection of superficial urothelial bladder cancer. <i>Cancer Genetics and Cytogenetics</i> , 2007, 173, 131-135.	1.0	31
14	Multiplex preamplification of specific cDNA targets prior to gene expression analysis by TaqMan Arrays. <i>BMC Research Notes</i> , 2008, 1, 21.	1.4	31
15	Plasma AR status and cabazitaxel in heavily-treated metastatic castration-resistant prostate cancer. <i>European Journal of Cancer</i> , 2019, 116, 158-168.	2.8	29
16	Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial. <i>BMC Medicine</i> , 2019, 17, 8.	5.5	28
17	Biomarkers vs conventional histological analysis to detect lymph node micrometastases in bladder cancer: a real improvement?. <i>BJU International</i> , 2012, 110, 1310-1316.	2.5	21
18	Molecular profiling of peripheral blood is associated with circulating tumor cells content and poor survival in metastatic castration-resistant prostate cancer. <i>Oncotarget</i> , 2015, 6, 10604-10616.	1.8	21

#	ARTICLE	IF	CITATIONS
19	Diving Into Cabazitaxel's Mode of Action: More Than a Taxane for the Treatment of Castration-Resistant Prostate Cancer Patients. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 265-270.	1.9	18
20	Utility of Urothelial mRNA Markers in Blood for Staging and Monitoring Bladder Cancer. <i>Urology</i> , 2012, 79, 240.e9-240.e15.	1.0	17
21	Taxane-induced Attenuation of the CXCR2/BCL-2 Axis Sensitizes Prostate Cancer to Platinum-based Treatment. <i>European Urology</i> , 2021, 79, 722-733.	1.9	17
22	Androgen Receptor and Its Splicing Variant 7 Expression in Peripheral Blood Mononuclear Cells and in Circulating Tumor Cells in Metastatic Castration-Resistant Prostate Cancer. <i>Cells</i> , 2020, 9, 203.	4.1	15
23	The influence of treatment sequence in the prognostic value of <i>TMPRSS2-ERG</i> as biomarker of taxane resistance in castration-resistant prostate cancer. <i>International Journal of Cancer</i> , 2019, 145, 1970-1981.	5.1	13
24	Co-expression of matrix metalloproteinase-7 (MMP-7) and phosphorylated insulin growth factor receptor I (pIGF-1R) correlates with poor prognosis in patients with wild-type KRAS treated with cetuximab or panitumumab: A GEMCAD study. <i>Cancer Biology and Therapy</i> , 2011, 11, 177-183.	3.4	8
25	Cell Plasticity-Related Phenotypes and Taxanes Resistance in Castration-Resistant Prostate Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 594023.	2.8	7
26	Glutamine and Cholesterol Plasma Levels and Clinical Outcomes of Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Taxanes. <i>Cancers</i> , 2021, 13, 4960.	3.7	7